Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease—A National Register Study

Tarik Almdalal, Pernilla Sundqvist, Ulrika Harmenberg, Mikael Hellström, Magnus Lindskog, Per Lindblad, Svan Lundstam, Börje Ljungberg

*Department of Surgery and Urology, Eskilstuna Country Hospital, Eskilstuna, Sweden; †Department of Urology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; ‡Department of Oncology, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden; §Department of Radiology, Sahlgrenska Academy/Sahlgrenska University Hospital, Gothenburg University, Gothenburg, Sweden; ‡Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; †School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; §Department of Urology and Oncology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; ‡Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden

Abstract

Background: T1a renal cell carcinoma (RCC) is typically considered a curable disease, irrespective of the choice of local treatment modality.

Objective: To identify factors associated with the risk of local and distant recurrence, and overall survival (OS) in patients with primary nonmetastatic clinical T1a RCC.

Design, setting, and participants: A population-based nationwide register study of all 1935 patients with cT1a RCC, diagnosed during 2005–2012, identified through The National Swedish Kidney Cancer Register, was conducted.

Outcome measurements and statistical analysis: Outcome variables were recurrence (local or distant) and OS. Possible explanatory variables included tumor size, RCC type, T stage, surgical technique, age, and gender. Associations with disease recurrence and OS were evaluated by multivariable regression and Cox multivariate analyses, respectively.

Results and limitations: Among 1935 patients, 938 were treated with radical nephrectomy, 738 with partial nephrectomy, and 169 with ablative treatments, while 90 patients had no surgery. Seventy-eight (4%) patients were upstaged to pT3. Local or metastatic recurrences occurred in 145 (7.5%) patients, significantly more often after ablation (17.8%). The risk of recurrence was associated with tumor size, upstaging, and ablation. Larger tumor size, disease recurrence, and older age adversely affected OS, whereas partial nephrectomy and chromophobe RCC (chRCC) were associated with improved survival. Limitations include register design and a lack of comorbidity or performance status data.

Conclusions: Upstaging and recurrence occurred, respectively, in 4.0% and 7.5% of patients with nonmetastatic RCCs ≤4 cm. Tumor size upstaging and ablation were
1. Introduction

The majority of solid renal masses are malignant tumors, mostly renal cell carcinomas (RCCs) [1]. The proportion of incidentally diagnosed RCCs has increased during the last decades, likely due to an increased use of cross-sectional imaging for a variety of unrelated causes [2,3]. The incidentally detected renal tumors have caused a stage shift in RCCs, with smaller tumors, with less advanced stage, and thus with a favorable prognosis [4,5]. The high percentage of detected small renal tumors, including a substantial proportion with benign histology, has reinforced the interest in active surveillance and nephron-sparing treatments [1,6]. As a group, small RCCs generally have been regarded as harmless [7]. However, for RCC, there remains a risk for local invasion and metastatic spread despite small tumor size [8]. Patients who subsequently develop metastases face a poor prognosis [8].

It is therefore highly important to evaluate the malignant potential of T1a RCCs to ensure that sufficient preoperative risk assessment is performed and that necessary treatments are given, but also to avoid overtreatment. It is further important to highlight possible risk factors for a more aggressive behavior. Upstaging from clinical T1a to pathological T3 at diagnosis has been shown to have a negative prognosis due to a higher risk for tumor recurrence and reduced survival [9].

The present study aimed to evaluate the occurrence of local recurrence and metachronous distant metastases in relation to the clinical and pathological factors and primary treatment of patients with nonmetastatic cT1a RCCs in a nationwide population of unselected RCC patients.

2. Patients and methods

2.1. Study design, setting, and participants

A total of 1935 patients, registered in the National Swedish Kidney Cancer Register (NSKCR) from January 2005 to the end of 2012 with clinical T1aM0 RCC at primary diagnosis, were included in the study. Patients with evidence of metastatic disease at diagnosis were excluded. Patients with cT1aM0 RCC were linked to the Swedish National Population Register for overall survival (OS) information. Information about the patient’s primary treatments, tumor-node-metastasis (TNM) stage, RCC type, Fuhrman grade, tumor size, and patient’s age and sex were extracted from the NSKCR. The TNM classification system and Fuhrman grade classification was used [10,11]. Seventeen patients registered as having Tx were reclassified to have T1a, having similar clinical behavior to T1a RCCs. Tumor size was defined as the maximal tumor diameter measured by computerized tomography (CT) or magnetic resonance imaging (MRI). All patients had potentially at least a 5-yr follow-up time for disease recurrence. Follow-up OS data were available for all 1935 patients until December 2019. At that time, 1429 (73.9%) patients were alive and 506 (26.1%) had died of any cause.

2.2. Statistical analyses and outcome measures

Outcome variables were recurrent disease (local or distant) and OS. OS time was defined as the time from diagnosis to the date of death from any cause or alive at the end of 2018.

Possible explanatory variables included age, gender, tumor size, RCC type (clear cell RCC [ccRCC], papillary RCC [pRCC], chromophobe RCC [chRCC], or other), and surgical technique (radical nephrectomy [RN], partial nephrectomy [PN], ablative treatment, or other). The category ablative treatment was a composite that included radiofrequency ablation (n = 142), cryoablation (n = 25), and high-intensity focused ultrasound (n = 2).

2.3. Selection bias

The NSKCR has a coverage of 99% of all RCCs diagnosed, compared with the Swedish Cancer Register where all patients with any cancer are reported according to the Swedish law. All Swedish citizens have a mandatory unique personal identity number that is used for the registration and follow-up on OS [12]. For the data presented in this paper, 15% of the patients’ charts (291 of 1935) were validated by NSKCR panel members. All patients primarily registered with a tumor size of <10 mm were intentionally validated. Mismatched data were revalidated and corrected for this analysis. The entire register has furthermore been validated showing high quality of the NSKCR data [13].

2.4. Statistical methods and missing data

The Mann-Whitney U test was used to compare medians and means of independent groups, while chi-square tests were performed for comparison of proportions. OS was estimated by the Kaplan-Meyer method and analyzed by the log-rank test. Multivariable analyses using logistic regression and Cox regression models were performed to identify potential prognostically independent variables. A two-tailed p value of <0.05 was considered statistically significant. Statistical analysis was performed using the SPSS version 22.

2.5. Ethical approval

The present study was approved by the regional Ethical Review Board of Northern Sweden (Dnr 2012-418-31M).
3. Results

Among the 1935 patients, 1192 (61.6%) were males and 743 (38.4%) females. Their mean age was 64.3 yr, ranging from 19 to 91 yr. Males were younger than females at diagnosis (mean 63.6 vs 65.3 yr, p = 0.002). Patients treated with PN were significantly younger than the other treatment groups (p < 0.001 for all), as shown in Table 1, and patients treated with RN were younger than patients treated with ablation (p = 0.038). Most (86.9%) patients were treated surgically, and 169 (8.7%) with ablation, and 84 (4.3%) were treated nonsurgically, as shown in Table 1.

There were 73.3% patients with ccRCC, 16.4% with pRCC, and 5.9% with chRCC, and 1.7% had unclassified RCC types. Fifty-one (2.6%) patients were registered with unknown histology. Among these, 39 were managed by nonsurgical treatments, ten with ablation, and one with RN, and one treated with other surgery. Of all patients with cT1a, 4.0% were upstaged to pT3 (Table 1). Most cT1a RCCs were registered with other surgery. Of all patients with treatments, ten with ablation, and one with RN, and one with recurrences, 22 developed local recurrence in the treated kidney only, while eight developed distant recurrent disease. Recurrence in the treated kidney only was registered in 12 PN patients (1.6%), significantly less frequent than after ablation (p < 0.001). There was no statistical difference in the occurrence of distant metastases in patients treated with ablation versus those treated with PN (p = 0.584, data not shown).

In a multivariable analysis, tumor size, type of treatment, and pT stage were associated with an increased risk for recurrent disease, while gender, age, and RCC type were not (Table 3). Tumor size had a hazard ratio (HR) of 1.05 (95% confidence interval [CI] 1.03–1.09), while patients upgraded to pT3 RCCs had an HR of 5.37 (95% CI 3.00–9.59). Patients treated with ablation had a five-fold elevated risk for recurrence (HR 5.62, 95% CI 3.23–9.95; Table 3).

At the time of data analysis, 74.6% (1385 of 1857) of patients with pT1a RCCs were alive compared with 56.4% more frequently than younger patients (8.6% vs 6.2%, p = 0.046). Twenty of 78 patients upstaged to pT3 (25.6%) developed recurrent disease, significantly more frequently than 125 of 1857 patients with pT1a (6.7%, p < 0.001). Recurrent disease was diagnosed in 15 patients with tumor size ≤2 cm compared with 130 patients with recurrence with tumor size varying from 2 to ≤4 cm (p = 0.006).

The recurrence rate was 7.7% for patients with ccRCC, 7.5% for pRCC patients, and 4.3% for patients with chRCC (Table 2). There was no difference in disease recurrences between patients treated with RN and PN (6.8% and 6.0%, respectively), while patients treated with ablative techniques had a higher rate (30 of 169, 17.8%) than patients treated with RN or PN (p < 0.001). Of 30 ablative patients with recurrences, 22 developed local recurrence in the treated kidney only, while eight developed distant recurrent disease. Recurrence in the treated kidney only was registered in 12 PN patients (1.6%), significantly less frequent than after ablation (p < 0.001). There was no statistical difference in the occurrence of distant metastases in patients treated with ablation versus those treated with PN (p = 0.584, data not shown).

Table 1 – Distribution of patient’s characteristics shown in relation to type of treatment in 1935 patients with cT1aM0 RCC

| Variable               | Radical nephrectomy (n = 938) | Partial nephrectomy (n = 738) | Ablation treatment (n = 169) | Other (n = 90) | All (n = 1935) |
|------------------------|--------------------------------|--------------------------------|--------------------------------|---------------|---------------|
| Age (yr)               | Mean a                          | 65.7                           | 60.6                           | 67.3          | 73.6          |
| Tumor size             | Median (range)                  | 67 (25–88)                     | 62 (19–85)                     | 68 (20–85)    | 75 (31–91)    |
| Gender                 | Men                             | 572                            | 460                            | 106           | 54            |
|                       | Women                           | 366 (39.0%)                    | 278 (37.7%)                    | 63 (37.3%)    | 743 (38.4%)   |
| T stage                | pT1a                            | 872                            | 727                            | 169           | 89            |
|                       | pT3a                            | 66 (7.0%)                      | 11 (1.5%)                      | 0             | 1 (1.1%)      |
| RCC type               | ccRCC                           | 746                            | 525                            | 114           | 1419          |
|                       | pRCC                            | 124                            | 155                            | 29            | 10            |
|                       | chRCC                           | 54                             | 50                             | 9             | 2             |
|                       | Other/unknown                   | 14                             | 8                              | 17            | 42            |
| Recurrent disease      | No                              | 874                            | 694                            | 139 d         | 83            |
|                       | Yes                             | 64 (6.8%)                      | 44 (6.0%)                      | 30 (17.8%)    | 7 (7.8%)      |
| Overall survival       | Alive                           | 637                            | 629                            | 127           | 36            |
|                       | Dead                            | 30 (32.1%)                     | 109 (14.8%)                    | 42 (24.9%)    | 54 (60.0%)    |

ccRCC = clear cell RCC; chRCC = chromophobe RCC; HIFU = high-intensity focused ultrasound; pRCC = papillary RCC; RCC = renal cell carcinoma.

Percentage is counted as gender, number of patients with upstaging to pT3 upstage, disease recurrence, and overall survival status in relation to the total number of comparable patients.

Ablation included radiofrequency ablation (n = 142), cryoablation (n = 25), and HIFU (n = 2). Other included eight patients with other surgeries and 82 without surgery.

a Patients with partial nephrectomy (PN) were younger than in the other treatment groups (p < 0.001 for all), patients with ablation were older than patients treated with radical nephrectomy (RN; p = 0.038).

b All treatment groups differed significantly in tumor size between each other (p < 0.001 for all except between other vs RN and PN, p = 0.001 and p = 0.12, respectively).

c RN had pT3 stage more often than PN (p < 0.001).

d Patients treated with ablation had recurrent disease significantly more often (p < 0.001).
(44 of 78) of patients with pT3 ($p < 0.001$). In the univariable analysis, age, type of treatment, T stage, RCC type, tumor size, and recurrent disease were associated significantly with OS, as exemplified in Fig. 1A–D. Using a Cox multivariate analysis, age, tumor size, type of treatment, and recurrent disease all were associated negatively with OS, while patients treated with nephron sparing and patients with chRCC had better OS (Table 4). Age was significantly linked to OS with an HR of 1.076 (95% CI 1.064–1.088) per year of age. In addition, tumor size was associated independently with an increased risk (HR 1.017, 95% CI 1.003–1.032, $p = 0.019$). Patients diagnosed with recurrent disease had a three-fold higher risk for overall death ($p < 0.001$). When subdividing recurrences into local recurrence in the treated kidney only and distant recurrent disease, no OS association was observed in patients with local recurrence (HR 0.944, 95% CI 0.376–2.372), while risk for reduced OS increased to 3.8 in patients with distant recurrences (HR 3.782, 95% CI 2.862–4.997). Using PN as a reference, patients treated with RN had 23% better OS in the multivariate analysis (HR 0.771, 95% CI 0.609–0.976), while ablation lacked an independent effect (Table 4). A 49% reduced risk for death was observed for patients with chRCC with an HR of 0.513 (95% CI 0.308–0.861, $p = 0.011$) compared with ccRCC, while there was no difference in OS between patients with ccRCC and those with pRCC (Table 4).

4. Discussion

This register study, based on all patients with RCC nationwide, shows that a non-negligible proportion of nonmetastatic RCCs ≤4 cm were upstaged to locally aggressive tumors or developed recurrence within 5 yr of follow-up. Small renal masses <4 cm in size have generally been regarded as indolent and equally treatable with nephron-sparing surgery, ablation, or surveillance [1]. This attitude is supported by the findings in many studies where 25–30% of small renal masses turn out to have a benign histology [14]. However, in the present study on nonmetastatic cT1a RCC, around 4% of the patients were upstaged to pT3, having renal vein and/or perinephric fat invasion, and in addition, 7.5% of the patients were diagnosed with distant recurrent disease within the 5-yr follow-up time.

Table 2 – Distribution of sites of disease recurrence in relation to histological tumor type in 145 patients among the 1935 patients with cT1aM0 renal cell carcinoma at primary diagnosis

| Site of recurrence | ccRCC (n = 1419) | pRCC (n = 318) | chRCC (n = 115) | Other/unknown (n = 83) | All a (n = 1935) |
|--------------------|-----------------|---------------|----------------|------------------------|-----------------|
| All                | 138             | 32            | 6              | 12                     | 188             |
| Lung               | 39              | 7             | 2              | 3                      | 51              |
| Treated kidney     | 27 (23 b)       | 11 (9 b)      | 3 (2 b)        | 4 (2 b)                | 45 (36 b)       |
| Skeletal           | 12              | 2             | 0              | 2                      | 16              |
| Lymph nodes        | 12              | 2             | 9              | 1                      | 15              |
| Adrenals           | 9               | 1             | 0              | 0                      | 10              |
| Contralateral kidney | 9              | 3             | 0              | 0                      | 12              |
| Liver              | 9               | 2             | 0              | 1                      | 12              |
| Adrenals           | 9               | 1             | 0              | 0                      | 10              |
| Local groin        | 4               | 2             | 0              | 1                      | 7               |
| Brain              | 4               | 1             | 0              | 0                      | 5               |
| Other              | 13              | 1             | 1              | 0                      | 15              |
| Patients with recurrences | 109             | 24            | 5              | 7                      | 145             |

ccRCC = clear cell renal cell carcinoma; chRCC = chromophobe renal cell carcinoma; pRCC = papillary renal cell carcinoma.

a Patients may have more than one site of recurrence: 33 patients had two recurrence sites, eight patients had three sites, and two patients had four sites registered.

b Patients with recurrent disease in the treated kidney only (when recurrences are subdivided into local recurrence in the treated kidney only).

Table 3 – Results of multivariate logistic regression analysis of factors important for the occurrence of recurrent disease in 1935 patients with nonmetastatic cT1 RCC

| Factor                | HR 95.0% CI for HR | p value |
|-----------------------|--------------------|---------|
| Age (yr)              | 1.010 0.994 1.030 | 0.255   |
| Gender (man vs woman) | 0.797 0.540 1.178 | 0.207   |
| Tumor size (mm)       | 1.053 1.029 1.089 | <0.001  |
| pT stage              | pTaRef. pT3a 5.365 | 3.002 9.590 | <0.001 |
| Treatment             | Rad. nephrectomyRef. 1.417 0.911 2.203 | 0.122  |
|                      | Ablation 5.672 3.232 9.953 | <0.001  |
| RCC type              | ccRCCRef. pRCC 0.526 0.564 1.521 | 0.761  |
|                      | chRCC 0.425 0.150 1.208 | 0.108  |

CI = confidence interval; ccRCC = clear cell RCC; chRCC = chromophobe RCC; HR = hazard ratio; pRCC = papillary RCC; RCC = renal cell carcinoma; Ref. = reference.

Patients (n = 129) treated with surveillance, other surgeries, and/or other and unknown RCC types were excluded from the analysis for clarity.
We showed that the risk of upstaging from cT1a to pT3 increased significantly by tumor size, in line with previous studies. Tan et al [15] reported 6.8% and Lee et al [16] reported 3.7% with pT3 upstage after a histopathological examination. The association between tumor size and upstaging to stage pT3 RCC was previously shown in an NSKCR study on cT1 RCCs [17] and in a recent meta-analysis [18]. Our present findings corroborate these reports, adding clinically important value by demonstrating that patients with upstaging have a significantly higher incidence of recurrent disease than those with pT1a RCC.

In the present study, we further found that a substantial proportion of patients (7.5%) were diagnosed with recurrent disease within a 5-yr follow-up time. The risk of recurrence was associated significantly with tumor size, with a 5% increase in the risk for each millimeter increase in size. Recently, Tan et al [15] published a single-center study of 565 patients with RCCs ≤4.0 cm, showing a 6% tumor
recurrence rate, associated with tumor size, presence of symptoms, and age above 65 yr. In our study representing a larger nationwide cohort including RCC patients only, we confirm the association of recurrence risk with tumor size, but not with age. Furthermore, we showed that the choice of treatment affected the risk of disease recurrence. Patients treated with ablative therapy had a 3.7 time higher risk for recurrence as compared with those treated with RN, in line with previous studies [19]. Albeit most recurrences after ablative treatment were local in the treated kidney, the proportion of patients with distant recurrent disease was not statistically different from that of surgically treated patients. Patients treated with PN did not have a higher risk of recurrence than patients treated with RN. Our findings indicate that patients treated with ablative techniques need a more frequent follow-up schedule than those treated with PN or RN.

In our study, RCC type was not associated with the risk of recurrence either in the univariate or in the multivariable analysis. While patients with ccRCC and pRCC had an equal proportion of recurrences, patients with chRCC had a non-significant trend for fewer recurrences. In a study of Tan et al [15], recurrent disease was observed in 6–8% of patients with ccRCCs and pRCCs, while none of 11 chRCC patients had any recurrence. Lee et al [16] found even lower recurrent rates: 3% for ccRCCs and 1.5% for pRCC, while none of 120 patients with chRCC got recurrent disease.

Women were significantly older than men in our study, in line with previous findings [20,21]. The reason for this difference in age distribution between genders is unclear. We found that females were treated with PN equally to men (38.6% vs 37.4%), in contrast to the findings of Metcalf et al [22], who found that gender differences persist in the management of cT1a RCC. In addition, Hadjipavlou et al [23] found that PN was associated with younger age, males, and smaller tumors. Neither age nor gender had any impact on the risk of disease recurrence in the present study.

Expectedly, an increase in age was significantly associated with OS, while gender was not. Patients treated with PN had significantly better OS than those treated with RN, as tested in a multivariate analysis adjusted for other potentially confounders. The OS advantage was expected in patients treated with PN, who were younger and possibly fitter than RN patients. However, the opposite applies for patients treated with ablation. These patients are generally older and have comorbidities more frequently, but these patients had no different OS from those treated with RN. Our finding with an OS advantage of the treatment with PN compared with RN opposes that of the only published randomized clinical study that found no survival benefit of PN [24]. However, that study was prematurely closed due to low inclusion, and only few patients were included yearly from each center, over a long time. It is well known that reduced renal function is associated with an increase in cardiovascular events and reduced OS [25]. Nephron-sparing approaches are supported in several nonrandomized studies [26–28]. The obvious advantage of nephron sparing is the preservation of renal function, while it also offers acceptable surgical morbidity, equivalent cancer control, and potential for better long-term survival [29].

Surprisingly, the univariate statistical significance of upstaging of cT1a to pT3 for OS did not remain significant when adjusted in the Cox analysis. In contrast, tumor recurrence, of any kind, was associated with a three-fold increase in the likelihood of death in the multivariable survival analysis. When subdivided, local recurrence in the treated kidney was not associated with a decreased OS risk, albeit having a broad CI. RCC type also influenced OS, with chRCC being an independent predictor of better survival. These results confirm previous studies on the prognostic impact of RCC type [30].

This register-based study has several important limitations. Clinical, radiological, and histopathological information was gathered from all Swedish hospitals, and chart data can be subjected to reporting errors. Moreover, the NSKCR did not contain information on performance status, comorbidities, pre- and postoperative complications, and cancer-specific survival. All patients, evaluated with CT or MRI at primary diagnosis, were treated based on patients’ and surgeons’ preferences. The strength of this material is that it represents real-world data of an unslected nationwide patient population with a 99% inclusion rate of newly diagnosed RCC in Sweden, which minimizes any selection bias, found in most other studies [31]. The long-term follow-up data and the highly valid data on OS strengthen the results obtained.

5. Conclusions

Patients with RCCs ≤4 cm without metastases at diagnosis have non-negligible risks of tumor upstaging and disease recurrence (4.0% and 7.5%, respectively). Tumor size, pathological upstaging, and ablative therapy were associated with disease recurrence. Furthermore, tumor size and disease recurrence were significantly associated with decreased OS, while patients with chRCC and those treated with PN were associated with improved OS.

**Author contributions:** Börje Ljungberg had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Ljungberg, Sundqvist.

**Acquisition of data:** Almadalal, Sundqvist, Harmenberg, Hellström, Lindblad, Lindskog, Lundstam, Ljungberg.

**Analysis and interpretation of data:** Almadalal, Ljungberg.

**Drafting of the manuscript:** Almadalal, Sundqvist, Ljungberg.

**Critical review of the manuscript for important intellectual content:** Almadalal, Sundqvist, Harmenberg, Hellström, Lindblad, Lindskog, Lundstam, Ljungberg.

**Statistical analysis:** Almadalal, Ljungberg.

**Obtaining funding:** Almadalal.

**Administrative, technical, or material support:** Almadalal, Ljungberg.

**Supervision:** Ljungberg, Sundqvist.

**Other:** None.

**Financial disclosures:** Börje Ljungberg certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript
(eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Tarik Almadadal and Pernilla Sundqvist: no conflict of interest. Ulrika Harmenberg: company speaker honorarium—Pfizer, BMS, and Ipsen; advisory boards—BMS and Ipsen. Mikael Hellström and Per Lindblad: no conflict of interest. Magnus Lindskog: advisory boards—BMS and Ipsen. Sven Lundstam: advisory boards—MSD, BMS, and Ipsen. Börje Ljungberg: company speaker honorarium—Novartis, Pfizer, Ipsen, and BMS; trial participation—Janssen, Astellas, and Medivation; company consultant—Janssen, Ipsen, and MSD; other—EAU.

Funding/Support and role of the sponsor: The study was supported by the Swedish Association of Local Authorities and Regions (SALAR) and the Clinical Research Center in the county of Sörmiland, Sweden.

Acknowledgments: This project was made possible by the continuous work of the NSKCR of Sweden steering group: Börje Ljungberg (chairman), Peter Elfving, Marcus Thomasson, Britt-Inger Kröger Dahlin, Annika Håkansson, Åsa Jelliver, Pernilla Sundqvist, Per Lindblad, Magnus Lindskog, Ulrika Harmenberg, Ann-Helén Scherman-Piogeli, Anders Kjellman, Andreas Thorstenson, Per Skoglund, Linn Pettersson, Emma Ulvsolg, Magnus Foveaus, Sven Lundstam, Mikael Hellström, Jörgen Jehander, and Martin Johansson. The authors also thank Soheila Hosseininia and other collaborators at the Regional Cancer Centre, Stockholm/Gotland, for continuous work with the register and providing data from the NSKCR.

References

[1] Ljungberg B, Albíges L, Abu-Ghanem Y, et al. European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol 2019;75:799–810.

[2] Thornstenson A, Harmenberg U, Lindblad P, Holmström B, Lundstam S, Ljungberg B. Characteristic and current treatments of patients with renal cell carcinoma in Sweden. Biomed Res Int 2015;2015:456040.

[3] Patard J-J. Incidental renal tumours. Curr Opin Urol 2009;19:454–8.

[4] Welch HG, Kramer BS, Black WC. Epidemiologic signatures in cancer. N Engl J Med 2019;381:1378–86.

[5] Lindsøk M, Wahlgren T, Sandrin R, et al. Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations. Urol Oncol 2017;35:541.e15–22.

[6] Wahlgren T, Harmenberg U, Sandström P, et al. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008). Br J Cancer 2013;108:1541–9.

[7] Campbell S, Uzzo RG, Allaf ME, et al. Renal mass and localized renal cancer: AUA guideline. J Urol 2017;198:520–9.

[8] Kunkle DA, Crispin PL, Li T, Uzzo RG. Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. J Urol 2007;177:1692–6.

[9] Umbrecht EC, Shimko MS, Childs MA, et al. Metastatic potential of a renal mass according to original tumour size at presentation. BJU Int 2012;109:190–4, discussion 194.

[10] Sobin LH, Wittekind CH, editors. TNM classification of malignant tumors. New York, NY: International Union Against Cancer and Wiley-Liss; 2002. p. 193–5.

[11] Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655–63.

[12] Ludvigsson JF, Otterblad-Glaousson P, Pettersson BU, Ekblom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009;24:659–67.

[13] Landberg A, Bruce D, Lindblad P, et al. Validation of data quality in the National Swedish Kidney Cancer Register. Scand J Urol 2021;55:142–8.

[14] Okhunov Z, Gorin MA, Jefferson FA, et al. Can preoperative renal mass biopsy change clinical practice and reduce surgical intervention for small renal masses? Urol Oncol 2021;39:735.e17–22.

[15] Tan YC, Khalid MFB, Villanueva A, Huang HH, Chen K, Sim ASP. Are small renal masses all the same? Int J Urol 2020;27:439–47.

[16] Lee H, Lee JK, Kim K, et al. Risk of metastasis for T1a renal cell carcinoma. World J Urol 2016;34:553–9.

[17] Ljungberg B, Gudmundsson E, Christensen S, Lundstam S. Swedish Kidney Cancer Quality Register Group. Practice patterns for the surgical treatment of T1 renal cell carcinoma: a nationwide population-based register study. Scand J Urol 2014;48:445–52.

[18] Veccia A, Falagarino U, Martini A, et al. Upstaging to pT3a in patients undergoing partial or radical nephrectomy for cT1 renal tumors: a systematic review and meta-analysis of outcomes and predictive factors. Eur Urol Focus 2021;7:574–81.

[19] Abro Blanco E, Domínguez Esteban M, Alonso Mediavilla E, et al. Percutaneous radiofrequency for the treatment of small renal masses: analysis of outcomes and complications after 10 years of experience. Actas Urol Esp 2021;45:273–80.

[20] Gudmundsson E, Hellborg H, Lundstam S, Erikson S, Ljungberg B. Swedish Kidney Cancer Quality Register Group. Metastatic potential in renal cell carcinomas <7 cm: Swedish Kidney Cancer Quality Register data. Eur Urol 2011;60:975–82.

[21] Bandini M, Marchioni M, Pompei RS, et al. The effect of age on cancer-specific mortality in patients with small renal masses: a population-based analysis. Can Urol Assoc J 2018;12:E325–30.

[22] Metcalf MR, Cheaib JG, Wainger J, et al. Gender differences in the clinical management of clinical T1a renal cell carcinoma. Urology 2021;151:129–37.

[23] Hadijipavlou M, Khan F, Fowler S, Joyce A, Keeley FX, Sriprasad S. Partial vs radical nephrectomy for T1 renal tumours: an analysis from the British Association of Urological Surgeons Nephrectomy Audit. BJU Int 2016;117:62–71.

[24] Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2007;51:1606–15.

[25] Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:306–17.

[26] Huang WC. Impact of nephron sparing on kidney function and non-oncologic mortality. Urol Oncol 2010;28:568–74.

[27] Thompson RH, Atwell T, Schmit G, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2015;67:232–9.

[28] Maclellan S, Imamura M, Lapitan MC, et al. Systematic review of oncological outcomes following surgical management of localised renal cancer. Eur Urol 2012;61:972–93.

[29] Nayan M, Saarella O, Lawson K, Martin L, Komisarenko M, Finelli A. Long-term outcomes after radical or partial nephrectomy for T1a renal cell carcinoma: a population-based study. Can Urol Assoc J 2020;14:392–7.

[30] Abu-Ghanem Y, Powles T, Capitanio U, et al. The impact of histological subtype on the incidence, timing, and patterns of recurrence in patients with renal cell carcinoma after surgery—results from RECUR Consortium. Eur Urol Oncol 2021;4:473–82.

[31] O’Malley RL, Hayn MH, Brewer KA, et al. Cancer control of partial nephrectomy for high-risk localized renal cell carcinoma: population-based and single-institutional analysis. World J Urol 2015;33:1807–14.